PMSA-targeted peptide radiopharmaceutical - Focus-X Therapeutics
Latest Information Update: 07 Dec 2022
Price :
$50 *
At a glance
- Originator Focus-X Therapeutics
- Class Antineoplastics; Peptide drug conjugates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer